Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-04-17
2010-10-19
Nguyen, Quang (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S455000, C536S023400
Reexamination Certificate
active
07816334
ABSTRACT:
The invention provides nucleic acid construct and nucleic acid expression vectors directing the expression of a fusion protein consisting of a disease peptide antigen and a first domain of FrC of tetanus toxin. The invention provides nucleic acid (DNA) vaccines for use in inducing an immune response against a disease. There is also provided methods of producing nucleic acid constructs and vectors for use as nucleic acid (DNA) vaccines.
REFERENCES:
patent: 6228621 (2001-05-01), Williams et al.
patent: 6534482 (2003-03-01), Fikes et al.
patent: 6936464 (2005-08-01), Zhu et al.
patent: WO 99/15671 (1999-04-01), None
Rice et al. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: Implications for cancer vaccines. J. Immunology 167:1558-1565, 2001.
Rice et al. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine 17:3030-3038, 1999.
Fairweather et al. Cloning, nucelotide sequencing, and expressionof Tetanus Toxin Fragment C inEscherichia coli. J. Bacteriology 165:21-27, 1986.
Panina-Bordignon et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237-2242, 1989.
Spellenberg, M.B., “DNA vaccines against lymphoma,” Journal of Immunology, 159:1885-1892, (1997).
Valmori, D., et al., “Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination,” Journal of Immunology, 149:717-721, (1992).
King, C.A., et al., “DNA vaccines with single-chain Fv fused to fragment C of tetanus toxi induce protective immunity against . . . ,” Nature Medicine, 4:1281-1286, (1998).
Herreros, J., et al., “C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a . . . ,” Biochemical Journal, 347:199-204, (2000).
Umland, T.C., et al., “Structure of the receptor binding fragment Hc of tetanus neurotoxin,” Nature Structural Biology, 4:788-792, (1997).
Rice Jason
Stevenson Freda
Cancer Research Technology Limited
Dann Dorfman Herrell & Skillman
Netter, Jr. Robert C.
Nguyen Quang
LandOfFree
Materials and methods relating to immune responses to fusion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods relating to immune responses to fusion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods relating to immune responses to fusion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201969